The identity of the RNA-binding proteins (RBPs) that govern cancer stem cells remains poorly characterized. The MSI2 RBP is a central regulator of translation of cancer stem cell programs. Through proteomic analysis of the MSI2-interacting RBP network and functional shRNA screening, we identified 24 genes required for in vivo leukemia. Syncrip was the most differentially required gene between normal and myeloid leukemia cells. SYNCRIP depletion increased apoptosis and differentiation while delaying leukemogenesis. Gene expression profiling of SYNCRIP-depleted cells demonstrated a loss of the MLL and HOXA9 leukemia stem cell program. SYNCRIP and MSI2 interact indirectly though shared mRNA targets. SYNCRIP maintains HOXA9 translation, and MSI...
To identify novel targets for acute myeloid leukemia (AML) therapy, we performed genome-wide CRISPR-...
Intratumoral heterogeneity is a common feature of many myeloid leukemias and a significant reason fo...
Acute myeloid leukemia (AML) is a heterogeneous disease with complex molecular mechanisms. Recent ad...
The identity of the RNA-binding proteins (RBPs) that govern cancer stem cells remains poorly charact...
<p>Mass spectrometry analysis of MSI2 interacting partners in K562 cells for manuscript "<strong>Fun...
The RNA-binding protein Musashi 2 (MSI2) has emerged as an important regulator in cancer initiation,...
RNA-binding proteins (RBPs) are essential modulators of transcription and translation frequently dys...
Aggressive myeloid leukemias such as blast crisis chronic myeloid leukemia and acute myeloid leukemi...
UNLABELLED: Acute myeloid leukemia (AML) is fueled by leukemic stem cells (LSC) whose determinants a...
RNA-binding proteins (RBPs) regulate many aspects of transcription and translation in a cell- and ti...
Tissue homeostasis is maintained after stress by engaging and activating the hematopoietic stem and ...
We recently generated 2 phenotypically similar Hoxa9+Meis1 overexpressing acute myeloid leukemias th...
RNA-binding proteins (RBPs) are critical regulators of post-transcriptional gene expression and aber...
available in PMC 2011 May 10.RNA-binding proteins of the Musashi (Msi) family are expressed in stem ...
Members of the basic Helix-Loop-Helix (bHLH) family of transcription factors play critical roles in ...
To identify novel targets for acute myeloid leukemia (AML) therapy, we performed genome-wide CRISPR-...
Intratumoral heterogeneity is a common feature of many myeloid leukemias and a significant reason fo...
Acute myeloid leukemia (AML) is a heterogeneous disease with complex molecular mechanisms. Recent ad...
The identity of the RNA-binding proteins (RBPs) that govern cancer stem cells remains poorly charact...
<p>Mass spectrometry analysis of MSI2 interacting partners in K562 cells for manuscript "<strong>Fun...
The RNA-binding protein Musashi 2 (MSI2) has emerged as an important regulator in cancer initiation,...
RNA-binding proteins (RBPs) are essential modulators of transcription and translation frequently dys...
Aggressive myeloid leukemias such as blast crisis chronic myeloid leukemia and acute myeloid leukemi...
UNLABELLED: Acute myeloid leukemia (AML) is fueled by leukemic stem cells (LSC) whose determinants a...
RNA-binding proteins (RBPs) regulate many aspects of transcription and translation in a cell- and ti...
Tissue homeostasis is maintained after stress by engaging and activating the hematopoietic stem and ...
We recently generated 2 phenotypically similar Hoxa9+Meis1 overexpressing acute myeloid leukemias th...
RNA-binding proteins (RBPs) are critical regulators of post-transcriptional gene expression and aber...
available in PMC 2011 May 10.RNA-binding proteins of the Musashi (Msi) family are expressed in stem ...
Members of the basic Helix-Loop-Helix (bHLH) family of transcription factors play critical roles in ...
To identify novel targets for acute myeloid leukemia (AML) therapy, we performed genome-wide CRISPR-...
Intratumoral heterogeneity is a common feature of many myeloid leukemias and a significant reason fo...
Acute myeloid leukemia (AML) is a heterogeneous disease with complex molecular mechanisms. Recent ad...